期刊文献+

CD133:A cancer stem cells marker, is used in colorectal cancers 被引量:19

CD133:A cancer stem cells marker, is used in colorectal cancers
下载PDF
导出
摘要 Colorectal cancer is one of the most common malignant tumors worldwide. A model of cancer development involving cancer stem cells has been put forward because it provides a possible explanation of tumor hierarchy. Cancer stem cells are characterized by their proliferation, tumorigenesis, differentiation, and selfrenewal capacities, and chemoradiotherapy resistance. Due to the role of cancer stem cells in tumor initiation and treatment failure, studies of cancer stem cell markers, such as CD133, have been of great interest. CD133, a five-transmembrane glycoprotein, is widely used as a marker to identify and isolate colorectal cancer stem cells. This marker has been investigated to better understand the characteristics and functions of cancer stem cells. Moreover, it can also be used to predict tumor progression, patient survival, chemoradiotherapy resistance and other clinical parameters. In this review, we discuss the use of CD133 in the identification of colorectal cancer stem cell, which is currently controversial. Although the function of CD133 is as yet unclear, we have discussed several possible functions and associated mechanisms that may partially explain the role of CD133 in colorectal cancers. In addition, we focus on the prognostic value of CD133 in colorectal cancers. Finally, we predict that CD133 may be used as a possible target for colorectal cancer treatment. Colorectal cancer is one of the most common malignant tumors worldwide. A model of cancer development involving cancer stem cells has been put forward because it provides a possible explanation of tumor hierarchy. Cancer stem cells are characterized by their proliferation, tumorigenesis, differentiation, and self-renewal capacities, and chemoradiotherapy resistance. Due to the role of cancer stem cells in tumor initiation and treatment failure, studies of cancer stem cell markers, such as CD133, have been of great interest. CD133, a five-transmembrane glycoprotein, is widely used as a marker to identify and isolate colorectal cancer stem cells. This marker has been investigated to better understand the characteristics and functions of cancer stem cells. Moreover, it can also be used to predict tumor progression, patient survival, chemoradiotherapy resistance and other clinical parameters. In this review, we discuss the use of CD133 in the identification of colorectal cancer stem cell, which is currently controversial. Although the function of CD133 is as yet unclear, we have discussed several possible functions and associated mechanisms that may partially explain the role of CD133 in colorectal cancers. In addition, we focus on the prognostic value of CD133 in colorectal cancers. Finally, we predict that CD133 may be used as a possible target for colorectal cancer treatment.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第17期2603-2611,共9页 世界胃肠病学杂志(英文版)
基金 Supported by Clinical Key Discipline Fund by Ministry of Health(2010-2012) Chinese National Clinical Key Discipline(2011-2012) the Shanghai Science and Technology Commission of Shanghai Municipality,No.10DJ1400500
关键词 CD133 COLORECTAL CANCER CANCER stem cells PROGNOSIS CHEMORADIOTHERAPY resistance CD133 Colorectal cancer Cancer stem cells Prognosis Chemoradiotherapy resistance
  • 相关文献

参考文献16

  • 1Zhi-Li Yang Qi Zheng Jun Yan Ye Pan Zhi-Gang Wang.Upregulated CD133 expression in tumorigenesis of colon cancer cells[J].World Journal of Gastroenterology,2011,17(7):932-937. 被引量:9
  • 2Shu-Wen Jao MD, MS,Su-Feng Chen PhD,Yaoh-Shiang Lin MD,Yun-Ching Chang PhD,Tsai-Yu Lee MD, MS,Chang-Chieh Wu MD, PhD,Jong-Shiaw Jin MD, PhD,Shin Nieh DDS, MS, MIAC.Cytoplasmic CD133 Expression is a Reliable Prognostic Indicator of Tumor Regression After Neoadjuvant Concurrent Chemoradiotherapy in Patients with Rectal Cancer[J].Annals of Surgical Oncology.2012(11)
  • 3Pierluigi Pilati MD,Simone Mocellin MD,Loris Bertazza PhD,Francesca Galdi PhD,Marta Briarava PhD,Enzo Mammano MD,Emanuela Tessari MD,Giorgio Zavagno MD,Donato Nitti MD.Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis[J].Annals of Surgical Oncology.2012(2)
  • 4Susumu Saigusa MD,Koji Tanaka MD,Yuji Toiyama MD,Takeshi Yokoe MD,Yoshinaga Okugawa MD,Yasuhiro Ioue MD, PhD,Chikao Miki MD, PhD,Masato Kusunoki MD, PhD.Correlation of CD133, OCT4, and SOX2 in Rectal Cancer and Their Association with Distant Recurrence After Chemoradiotherapy[J].Annals of Surgical Oncology.2009(12)
  • 5Naotsugu Haraguchi MD, PhD,Masahisa Ohkuma MD,Hiroyuki Sakashita MD,Shinji Matsuzaki MD,Fumiaki Tanaka MD, PhD,Koshi Mimori MD, PhD,Yukio Kamohara MD, PhD,Hiroshi Inoue MD, PhD,Masaki Mori MD, PhD.CD133+CD44+ Population Efficiently Enriches Colon Cancer Initiating Cells[J].Annals of Surgical Oncology.2008(10)
  • 6Keisuke Ieta MD, PhD,Fumiaki Tanaka MD, PhD,Naotsugu Haraguchi MD, PhD,Yoshiaki Kita MD,Hiroyuki Sakashita MD,Koshi Mimori MD, PhD,Toshifumi Matsumoto MD, PhD,Hiroshi Inoue MD, PhD,Hiroyuki Kuwano MD, PhD,Masaki Mori MD, PhD.Biological and Genetic Characteristics of Tumor-Initiating Cells in Colon Cancer[J].Annals of Surgical Oncology.2008(2)
  • 7PC Hermann,SL Huber,T Herrler.Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer[].Cell Stem Cell.2007
  • 8LaBarge MA et al.Is CD133a marker of metastatic colon cancer stem cells?[].The Journal of Clinical Investigation.2008
  • 9Yanagisawa S,Kadouchi I,Yokomori K, et al.Identification and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney[].Clinical Cancer Research.2009
  • 10SCHNEIDER M,HUBER J,HADASCHIK B,et al.Characterization of colon cancer cells:a functional approach characterizing CD133as a potential stem cell marker[].BMC Cancer.2012

二级参考文献31

  • 1Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99:1285-1289.
  • 2Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008; 99: 1578-1583.
  • 3Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010; 70:719-729.
  • 4Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 2003; 83:173-180.
  • 5Weiswald LB, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordeli-res FP, Bertrand F, Dargere D, Massonnet G, Marangoni E, Gayet B, Pocard M, Bieche I, Poupon MF, BeUet D, Dangles-Marie V. Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br J Cancer 2009; 101:473482.
  • 6Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroidbased drug screen: considerations and practical approach. Nat Protoc 2009; 4:309-324.
  • 7Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008; 14: 6751-6760.
  • 8Horst D, Scheel SK, Liebmarm S, Neumarm J, Maatz S, Kirchner T, Jung A. The cancer stem cell marker CD133 has high prognostic impact but unknown hanctional relevance for the metastasis of human colon cancer. J Pathol2009; 219:427-434.
  • 9Zhu L Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, EUison DW, Gflbertson RJ. Prominin I marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457:603-607.
  • 10Barker N, van Es J-H, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem ceils in small intestine and colon by marker gene Lgr5. Nature 2007; 449:1003-1007.

共引文献8

同被引文献550

引证文献19

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部